glp-1 trial results today Major Advancement in Obesity Treatment: Oral Announced Eli Lilly announced positive topline results from the Phase 3 ATTAIN-1 trial of orforglipron, a once-daily oral GLP-1 receptor agonist for obesity Potential Breakthrough to Preserve Lean

Bottom Line on Cost: For Cash-Pay Patients: Best value: Compounded semaglutide at $199/month Maximum results: Compounded tirzepatide at $349/month Avoid: Brand-name at $1,000+/month (unsustainable) With Good Insurance: Try savings cards: May get $25/month brand-name If high copays: Compounded may be cheaper Factor in: Total out-of-pocket including deductibles Plan for long-term treatment costsobesity is a chronic condition requiring sustained therapy

jot.2022.02.001

A recent New York Post report covered a trial where patients on Ozempic showed measurable reductions in biological age, over three years younger, on average, according to epigenetic testing

The biggest concern is the disconnect between how intoxicated patients feel and what their alcohol blood level is, says Neha Agrawal, Director of Clinical Pharmacy Services at Legacy Community Health

However, high prices and limited insurance coverage continue to restrict access for many patients